Table 1.
Baseline characteristics of the study population (n=39)
| Parameter | Twice daily dosing n (%) or mean ± SD |
|---|---|
| Number of patients | 39 |
| Age (years) | 69.7 ± 11.7 |
| Women | 16 (42.1) |
| Medical history | |
| Chronic kidney disease | 39 (100) |
| Diabetic kidney | 18 (46.1) |
| Benign nephrosclerosis | 11 (28.2) |
| IgA kidney | 4 (10.2) |
| Gouty kidney | 4 (10.2) |
| Nephropathy of pregnancy | 1 (2.5) |
| Hepatorenal syndrome | 1 (2.5) |
| eGFR (ml/min/1.73 m2) | 49.0 ± 28.3 |
| G1 | |
| ≥90 | 1 (2.5) |
| G2 | |
| 60–89 | 12 (30.7) |
| G3a | |
| 45–59 | 10 (25.6) |
| G3b | |
| 30–44 | 5 (12.8) |
| G4 | |
| 15–29 | 6 (15.3) |
| G5 | |
| <15 | 5 (12.8) |
Abbreviations: eGFR, estimated glomerular filtration rate; G, stages of chronic kidney disease; IgA, immunoglobulin A; SD, standard deviation.